# Prostatic Neoplasms FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/prostatic-neoplasms

> 8 upcoming FDA catalysts in prostatic Neoplasms: Erleada (apalutamide, JNJ) on December 2026 (primary completion); Erleada (apalutamide, JNJ) on Dec 2026 to Mar 2027 (topline data readout); JNJ-101556143 (JNJ) on Feb to May 2028 (topline data readout); JNJ-101556143 (JNJ) on February 2028 (primary completion); and 4 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 2026 | [Erleada (apalutamide) primary completion](https://sec-api.dev/pdufa/apalutamide) | JNJ | Prostatic Neoplasms | scheduled | "NCT03767244 (A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03767244)) |
| Dec 2026 to Mar 2027 | [Erleada (apalutamide) topline data readout](https://sec-api.dev/pdufa/apalutamide) | JNJ | Prostatic Neoplasms | scheduled | "NCT03767244 (A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03767244)) |
| Feb to May 2028 | [JNJ-101556143 topline data readout](https://sec-api.dev/pdufa/jnj-101556143) | JNJ | Prostatic Neoplasms | scheduled | "NCT07906717 (A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-14 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07906717)) |
| February 2028 | [JNJ-101556143 primary completion](https://sec-api.dev/pdufa/jnj-101556143) | JNJ | Prostatic Neoplasms | scheduled | "NCT07906717 (A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-14 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07906717)) |
| May to Aug 2029 | [JNJ-101556143 topline data readout](https://sec-api.dev/pdufa/jnj-101556143) | JNJ | Prostatic Neoplasms | scheduled | "NCT07832292 (A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-17 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07832292)) |
| May 2029 | [JNJ-101556143 primary completion](https://sec-api.dev/pdufa/jnj-101556143) | JNJ | Prostatic Neoplasms | scheduled | "NCT07832292 (A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-17 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07832292)) |
| Aug to Nov 2029 | [Erleada (apalutamide) topline data readout](https://sec-api.dev/pdufa/apalutamide) | JNJ | Prostatic Neoplasms | scheduled | "NCT04557059 (A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-08-27 (ESTIMATED); Lead Sponsor Janssen Pharmaceutica N.V., Belgium." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04557059)) |
| August 2029 | [Erleada (apalutamide) primary completion](https://sec-api.dev/pdufa/apalutamide) | JNJ | Prostatic Neoplasms | scheduled | "NCT04557059 (A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-08-27 (ESTIMATED); Lead Sponsor Janssen Pharmaceutica N.V., Belgium." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04557059)) |

## Drugs

- [Erleada (apalutamide)](https://sec-api.dev/pdufa/apalutamide) (JNJ)
- [JNJ-101556143](https://sec-api.dev/pdufa/jnj-101556143) (JNJ)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/prostatic-neoplasms.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Prostatic Neoplasms FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/prostatic-neoplasms

```bibtex
@misc{secapidev_indications_prostatic_neoplasms_20261116,
  title        = {Prostatic Neoplasms FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/prostatic-neoplasms}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_prostatic_neoplasms_20261116","title":"Prostatic Neoplasms FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/prostatic-neoplasms","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
